GO
Loading...

Life Sciences

More

  • LONDON, Dec 11- GAVI, the global vaccines alliance, has committed up to $300 million to buy Ebola vaccines and is ready to begin procurement as soon as the World Health Organisation recommends one for use, the alliance said on Thursday. Up to an additional $90 million could also be used to support countries to introduce the vaccines and to rebuild their health...

  • New HPV vaccine strengthens cancer protection Wednesday, 10 Dec 2014 | 3:22 PM ET

    WASHINGTON— The drugmaker Merck& Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer. The FDA said Wednesday the updated Gardasil has the potential to prevent roughly 90 percent of cervical, vulvar, vaginal and anal cancers.

  • Arca's potential Ebola drug gets "orphan drug status" Wednesday, 10 Dec 2014 | 11:19 AM ET

    Dec 10- Arca Biopharma Inc said the U.S. Food and Drug Administration granted its experimental drug orphan drug status as a potential treatment for viral hemorrhagic fever after exposure to the Ebola virus. The Westminster, Colorado- based company, whose stock rose about 11 percent on Wednesday, joins a list of drugmakers looking for ways to fight the largest...

  • This data represents a "quantum leap" in the management of this disorder by shifting from "life-long symptom management to once-and-done cures," Roth Capital Partner's Debjit Chattopadhyay said, raising his price target on the stock to $90 from $50. LentiGlobin's results read-through favorably to the sickle-cell indication, Piper Jaffray analysts said,...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...

  • Dec 3- U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date. Anthony Stein, professor of hematology at City of Hope outside Los Angeles who worked on clinical trials of blinatumomab, called the approval "very important" for patients.

  • FDA panel says newer HIV tests effective Tuesday, 2 Dec 2014 | 5:00 PM ET

    Dec 2- Newer methods to test donated blood samples for HIV infections are effective, a panel of experts at the U.S. Food and Drug Administration concluded, in a move that could limit the ban on donations by men who have had sex with other men. The FDA's ban, in place for about three decades, disallows donations from men who have had sex with even one man since 1977, as they...

  • *Developed by UniQure and marketed in Europe by Chiesi. FRANKFURT/ LONDON, Nov 26- The Western world's first gene therapy drug is set to go on sale in Germany with a 1.1 million euro price tag, a new record for a medicine to treat a rare disease. The sky-high cost of Glybera, from Dutch biotech firm UniQure and its unlisted Italian marketing partner Chiesi, shows how...

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • UPDATE 1-Juno Therapeutics files for IPO Monday, 17 Nov 2014 | 7:23 AM ET

    Nov 17- Juno Therapeutics Inc, a biopharmaceutical company that is working on cancer treatments, filed with U.S. regulators for an initial public offering of common stock. Seattle- based Juno, which has raised more than $310 million in funding since April this year, counts venture capital firm ARCH Venture Fund VII LP as one of its major investors, with a stake of...

  • Juno Therapeutics files for IPO Monday, 17 Nov 2014 | 6:32 AM ET

    Nov 17- Juno Therapeutics Inc filed with U.S. regulators for an initial public offering of its common stock. Morgan Stanley, J.P. Morgan and Goldman Sachs& Co were underwriting the IPO, the biopharmaceutical company told the U. S Securities and Exchange Commission in a preliminary prospectus on Monday. The filing included a nominal fundraising target of about...

  • DAKAR/ BRUSSELS, Nov 14- Medecins Sans Frontiers "wasted time" by waiting too long to call for vaccines to fight an unprecedented outbreak of Ebola in West Africa, a veteran of the medical charity told Reuters. The group's response to the epidemic which has so far killed more than 5,000 people has been widely praised by governments and the World Health Organization.

  • Nov 10- Cancer vaccine maker Dendreon Corp filed for Chapter 11 bankruptcy protection on Monday after its potential blockbuster cancer drug failed to live up to expectations, saddling the company with heavy debt. Dendreon's stock was down nearly 62 percent at 36 cents in premarket trading. Under the agreements, senior noteholders will support a plan of...

  • NEW YORK, Nov 9- Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros in Ebola research, with the lion's share going to the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and the...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros into Ebola research, with the lion's share going to fast-track the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and...

  • TOKYO, Oct 30- Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company...

  • UPDATE 1-Pfizer meningitis vaccine wins U.S. approval Wednesday, 29 Oct 2014 | 3:06 PM ET

    Oct 29- Pfizer Inc has won U.S. approval for its Trumenba vaccine against meningitis, a potentially deadly bacterial disease that has recently caused outbreaks on college campuses, the U.S. Food and Drug Administration said on Wednesday. It is the first approved U.S. vaccine that prevents invasive disease caused by the bacterium Neisseria meningitidis B, a...

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...